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REVIEW
Abstract: Cushing’s syndrome is a consequence of primary or, more commonly, secondary
oversecretion of cortisol. Cardiovascular disease is the major cause of morbidity and mortality
in Cushing’s syndrome, and excess risk remains even in effectively treated patients. The
cardiovascular consequences of cortisol excess are protean and include, inter alia, elevation
of blood pressure, truncal obesity, hyperinsulinemia, hyperglycemia, insulin resistance, and
dyslipidemia. This review analyses the relationship of cortisol excess, both locally and at
tissue level, to these cardiovascular risk factors, and to putative mechanisms for hypertension.
Previous studies have examined correlations between cortisol, blood pressure, and other
parameters in the general population and in Cushing’s syndrome. This review also details
changes induced by short-term cortisol administration in normotensive healthy men.
Keywords: blood pressure, cortisol, Cushing’s syndrome, risk factors
Introduction
Cortisol, the major human glucocorticoid, is essential for maintenance of normal
blood pressure and in excess, either general or local, produces hypertension (Kelly,
Mangos, et al 1998). Naturally occurring glucocorticoid hypertension in its most
florid form, Cushing’s syndrome, is rare. It is estimated to affect 1 in 300–400
hypertensives in referral centres, and around 5–25 per million of the general
population. Iatrogenic Cushing’s syndrome, on the other hand, is common. Widely
used clinically, synthetic glucocorticoids are said to cause hypertension in some 20%
of patients, but steroids invariably raise blood pressure in experimental studies
(Whitworth et al 1989). There is considerable interest in the notion that cortisol may
play a role in some forms of essential hypertension and it has been suggested that
cortisol may contribute to around 30% of all cases of hypertension (Walker et al
1991; Soro et al 1995; Mangos, Kelly, et al 2000). There is interest in the role of
cortisol in determination of cardiovascular risk (Walker et al 1998; Fraser et al 1999;
Girod et al 2004).
We have previously examined hemodynamic, volume, metabolic, and hormonal
effects of cortisol in a series of studies which have defined the characteristics of
cortisol-induced hypertension in normotensive healthy men (Whitworth, Saines, et
al 1984; Connell et al 1987; Pirpiris et al 1993; Wong et al 1993; Whitworth et al
1994, 1994a, 1994b; Williamson et al 1996; Tam, Kelly, et al 1997; Tam, Williamson,
et al 1997; Kelly, Tam, et al 1998; Macefield et al 1998). In this review, we discuss
changes in cardiovascular risk factors produced by cortisol and factors which might
contribute to the blood pressure rise. There is a large range of literature on effects of
synthetic glucocorticoids, such as prednisolone and dexamethasone, but this review
is confined to consideration of the major naturally occurring adrenocorticosteroid
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hormone, cortisol. The effect of the synthetic steroid
dexamethasone on cardiovascular biomarkers has been
delineated recently by Brotman, Girod, et al (2005).
Cardiovascular risk factors
Excess cardiovascular morbidity and mortality is a feature
of Cushing’s syndrome (Etxabe and Vazquez 1994).
Untreated Cushing’s syndrome has a poor prognosis, with
only a 50% 5-year survival. Even in treated Cushing’s
syndrome, morbidity remains high, with a very substantial
contribution from cardiovascular disease (Ross and Linch
1982; Etxabe and Vazquez 1994; Colao et al 1999). In
subclinical Cushing’s syndrome, both systolic and
diastolic blood pressures were significantly elevated
compared with controls due to incidentally discovered
adrenal adenoma with mild autonomous cortisol
hyperproduction (Tauchmanova et al 2002). Patients treated
with glucocorticoids also have significantly increased risk
of cardiovascular and cerebrovascular disease (Souverein
et al 2004; Wei et al 2004).
Hypertension
There is good evidence that the elevated blood pressure seen
in Cushing’s syndrome is a consequence of adrenocortico-
trophic hormone (ACTH) stimulated increases in cortisol
secretion. We have shown that ACTH reproducibly increases
blood pressure in both healthy normotensive and hyper-
tensive subjects, but not in patients with Addison’s disease
on steroid replacement. This indicates ACTH hypertension
is adrenally dependent (Whitworth et al 1983). We
subsequently showed that the blood pressure raising effects
of ACTH were reproduced by cortisol infusion appropriate
for conditions of ACTH stimulated cortisol secretion
(Whitworth, Saines, et al 1984). Although ACTH receptors
have been demonstrated in human aortic endothelial cells
(Hatakeyama et al 2000), it seems unlikely that direct actions
of ACTH are involved in ACTH hypertension in humans.
Cortisol excess was correlated with the hypertension in
Cushing’s syndrome in a case report (Suzuki et al 1992),
and in 28 patients (Soszynski et al 1991), but not in all studies
(Sonino et al 1992). There is no relationship between
mineralocorticoid excess and hypertension, and no
difference between concentrations of other adrenocortical
steroids in Cushing’s syndrome and essential hypertension
(Whitworth et al 2004). Spironolactone, a mineralocorticoid
antagonist, did not significantly lower blood pressure in
patients with Cushing’s syndrome (Saruta 1996). These
observations, together with experimental studies using
cortisol, indicate that cortisol is very likely the responsible
steroid in the hypertension of Cushing’s syndrome.
Hypertension was a feature of 9/12 of Cushing’s original
cases (Danese and Aron 1994) and is found in around 80%
of cases (Plotz et al 1952). We have shown that adminis-
tration of cortisol to normotensive healthy men reproducibly
raises blood pressure (Whitworth, Saines, et al 1984; Connell
et al 1987; Whitworth et al 1994, 1994a, 1994b; Williamson
et al 1996). The increase in plasma cortisol concentration
produced by cortisol at 200 mg/day was associated with a
highly significant rise in systolic blood pressure (Table 1).
There is some evidence that cortisol excess may be a
feature of essential hypertension. Litchfield and colleagues
(1998) found higher urinary free cortisol excretion in
153 white patients with essential hypertension than 18
normotensive controls. The authors of the Four Corners
Study (Watt et al 1992) observed higher plasma cortisol
concentrations in 50 young people with high blood pressure
and high parental blood pressure compared with similar
numbers of people with lower pressure. Morning plasma
cortisol concentrations were elevated in untreated male
hypertensives selected from the Paris Prospective Study
(total cohort n = 6424) (Filipovsky et al 1996). Systolic blood
pressure was related to fasting plasma cortisol concentration
Table 1 Effects on cardiovascular risk factors of cortisol
administration (200 mg/day) for 5 days in normotensive healthy
men
Parameter n Control Cortisol p
Plasma cortisol (nmol/L) 33 402 ± 21 1045 ± 73 < 0.001
Systolic blood pressure (mmHg) 33 117 ± 1 129 ± 1<  0.001
Body weight (kg) 8 70.4 ± 2.8 71.4 ± 2.8 < 0.001
Fasting plasma glucose (mmol/L) 46 4.1 ± 0.1 5.0 ± 0.2 < 0.001
Plasma insulin (mU/L 11 16 ± 2.1 22.8 ± 2.1 0.05
HOMA 11 1.25 ± 0.18 1.44 ± 0.14 ns
Plasma cholesterol (mmol/L) 10 4.3 ± 0.3 4.3 ± 0.3 ns
HDL (mmol/L) 10 1.1 ± 0.1 1.3 ± 0.1 ns
LDL (mmol/L) 10 2.7 ± 0.3 2.6 ± 0.3 ns
Plasma triglycerides (mmol/L) 10 1.2 ± 0.9 1.1 ± 0.5 ns
Plasma homocysteine (µmol/L) 6 9.32 ± 0.87 9.72 ± 0.85 ns
Plasma urate (mmol/L) 6 0.37 ± 0.03 0.28 ± 0.01 0.015
Plasma vitamin C (µmol/L) 6 29.0 ± 6.7 27.0 ± 4.7 ns
Plasma vitamin E (µmol/L) 6 24.0 ± 0.7 21.2 ± 2.1 ns
Plasma t-PA (ng/ml) 6 8.6 ± 0.7 7.4 ± 0.8 0.025
Plasma PA-1 (ng/ml) 8 6.2 ± 1.3 3.6 ± 1.3 ns
Corrected serum calcium (mmol/L) 8 2.33 ± 0.02 2.32 ± 0.01 ns
NOTE: Results shown as mean ± s.e.m.
Abbreviations: n, number of subjects; HOMA, homeostasis model assessment
score; HDL, high density lipoproteins; LDL, low density lipoproteins; ns,
nonsignificant; t-PA, tissue plasminogen activator; PA-1, plasminogen activator
inhibitor -1Vascular Health and Risk Management 2005:1(4) 293
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in a cohort of 370 English men (Phillips et al 1998), but
Fraser et al (1999) found no correlation of cortisol excretion
rate with blood pressure in 439 normal Scots. Walker et al
(2000) examined 226 Swedish subjects in a cross-sectional
study and found higher plasma cortisol was independently
associated with higher diastolic blood pressure in men, but
not women. In another study of 593 English subjects, higher
cortisol under the curve during oral glucose tolerance testing
was associated with higher systolic blood pressure
(Reynolds et al 2003). In an Indian cohort of 509 subjects,
9 am cortisol was strongly associated with systolic and
diastolic blood pressure (Ward et al 2003). Sensitivity to
glucocorticoids was also increased in 11 patients with
essential hypertension compared with matched normo-
tensive controls (Walker et al 1996).
Phillips (2004) has reviewed evidence for the concept
of fetal programming of the neuroendocrine response to
stress and the association of increased adrenocortical and
sympathoadrenal responses with small size at birth.
The observation that peroxisome proliferator-activated
receptor agonists lower blood pressure in humans (Hirose
et al 2002) is of interest in this regard given their observed
effects on downregulation of 11 beta-hydroxysteroid
dehydrogenase 1 (11β-HSD1), and hence availability of
biologically active glucocorticoids (Berger et al 2001).
Obesity
Truncal obesity is a hallmark of Cushing’s syndrome.
Patients with Cushing’s disease (n = 25) had higher body
mass index and waist to hip ratio than age and sex matched
controls (Faggiano et al 2003). These features persisted in
15 patients who had been cured over 5 years previously
(Colao et al 1999). In our studies of short-term cortisol
administration (200 mg/day) in normotensive healthy men,
weight gain is a feature (Table 1) and most likely represents
salt and water retention over the 5-day period (Connell et al
1987) (see below).
Cortisol excretion rate correlated positively with body
mass index and waist and hip measurements in both men
and women in a general Scottish population (n = 439), with
the relationship persisting in men after multiple regression
analysis (Fraser et al 1999). A rise of morning salivary
cortisol correlated with body mass index, waist-hip ratio,
and abdominal sagittal diameter in 28 Swedish men
(Wallerius et al 2003). As discussed by Fraser et al (1999),
the majority of, but not all, studies (Stolk et al 1996) found
a correlation of urinary cortisol excretion with measures of
obesity. Although cortisol excretion was increased,
circulating cortisol was not high in most subjects. Indeed,
although cortisol secretion is elevated, circulating
concentrations may be normal or low (Bjorntorp and
Rosmond 2000). Stolk and colleagues (1996) speculated
that the clear effects of cortisol hypersecretion on body fat
as compared with the difficulty in identifying the relationship
in normal subjects may reflect differences in potency of
cortisol at the target tissue level. In this context, Bujalska et
al (1997) suggested central obesity may reflect “Cushing’s
disease of the omentum”. They found adipose stromal cells
from omental, but not subcutaneous fat, can generate active
cortisol from inactive cortisone through expression of
11β-HSDI, and that enzyme expression was increased after
exposure to cortisol and insulin. They concluded that in vivo,
such a mechanism would ensure constant glucocorticoid
exposure specifically to omental fat, leading to central
obesity (Bujalska et al 1997). This group has subsequently
shown that in intact undifferentiated omental adipose stromal
cells, 11β-HSDI acts primarily as a dehydrogenase, but in
mature cells oxoreductase activity dominates. They
postulated that as glucocorticoids inhibit cell proliferation,
11β-HSDI activity in uncommitted cells may facilitate
proliferation, but once early differentiation is initiated, a
switch to oxoreductase activity generates cortisol, promoting
adipogenesis (Bujalska et al 2002). Whorwood and
colleagues (2001, 2002) have speculated that regulation of
glucocorticoid receptor isoforms and 11β-HSDI expression
in skeletal muscle may play a key role in insulin resistance
and that increased receptor expression may contribute to
pathogenesis of the metabolic syndrome.
Hyperglycemia
Glucose intolerance and diabetes mellitus are very common
in Cushing’s syndrome. Fasting glucose was significantly
higher in patients with Cushing’s than those in remission
(Terzolo et al 2004), and in patients (n = 25) than age and
sex matched controls (Faggiano et al 2003). Elevated fasting
glucose is also a feature of subclinical Cushing’s syndrome
(Tauchmanova et al 2002). Fasting plasma glucose elevation
is a common accompaniment of cortisol administration. In
our studies, fasting plasma glucose rose consistently in
normotensives after 5 days of cortisol administration
(Table 1).
Both fasting and 2-hour stimulated plasma glucose
concentrations correlated with 9 am fasting plasma cortisol
in the cohort of 370 healthy men born in the UK betweenVascular Health and Risk Management 2005:1(4) 294
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1920 and 1930 studied by Phillips et al (1998). Walker et al
(1998) found increased dermal sensitivity to glucocorticoid
correlated with hyperglycemia as well as with hypertension
and insulin resistance in 137 men. Wallerius et al (2003)
reported a rise in morning salivary cortisol correlated with
glucose in 28 Swedish men. In a large study from England
(n = 593), Reynolds et al (2003) found plasma cortisol and
obesity had independent effects on plasma glucose (although
independence should not be interpreted as causality
[Brotman, Walker, et al 2005]). In a healthy South Asian
cohort from Mysore (n = 509), fasting glucose was strongly
associated with 9 am plasma cortisol (Ward et al 2003). In
patients with glucose intolerance, Andrews et al (2002)
reported that cortisol secretion, although normal, is
inappropriately high given enhanced peripheral sensitivity
to glucocorticoids.
Insulin resistance
Insulin resistance is a feature of cortisol excess, both in
clinical (Tauchmanova et al 2002; Faggiano et al 2003) and
experimental settings (Connell et al 1987). Elevated insulin
persists 5 years after cure of Cushing’s disease (Colao et al
1999). Short-term cortisol administration in our studies of
healthy men produced a significant increase in plasma
insulin concentration but the homeostasis model assessment
score, a measure of insulin resistance, was not significantly
increased (Table 1).
The relationship between glucocorticoids and insulin
resistance has been reviewed by Andrews and Walker (1999).
Phillips et al (1998) examined the relationships between
size at birth, plasma cortisol concentrations, and components
of the insulin resistance syndrome in a cohort of 370 healthy
English men born between 1920–1930. Fasting plasma
cortisol concentrations were related to systolic blood
pressure; plasma glucose: both fasting and 2 hours after an
oral glucose tolerance test; plasma triglycerides; and insulin
resistance. However, in 151 elderly Finnish women, 24-hour
salivary cortisol did not correlate with the metabolic
syndrome or birth size (Kajantie et al 2004).
A positive correlation between morning plasma cortisol
concentration and fasting insulin concentration has been
reported in healthy elderly Dutch women (Stolk et al 1996).
In a Finnish study of 71 healthy men, the insulin resistance
and hyperinsulinemia of centrally obese subjects was
associated with increased urinary cortisol excretion, but
circulating cortisol levels were low (Hautanen et al 1997).
Wallerius et al (2003) found a positive association of a rise
in morning salivary cortisol with insulin concentration, and
Ward et al (2003) found a positive association between 9 am
cortisol and insulin resistance in a healthy South Asian
population (n = 509) born in Mysore between 1934–1954.
Walker et al (1998) found increased dermal glucocorticoid
sensitivity is associated with relative hypertension, insulin
resistance, and hyperglycemia in men, including those with
a genetic predisposition to hypertension.
Reynolds and colleagues (2002) examined skeletal
muscle biopsies from 23 men without fasting hyperglycemia
from the Uppsala Longitudinal Study of Adult Men. After
adjusting for body mass index, higher levels of skeletal
muscle glucocorticoid receptor messenger ribonucleic acid
(mRNA) were associated with insulin resistance and with
hypertension, but not plasma lipids, glucose, or body mass
index alone. They suggested tissue specific variations in
glucocorticoid receptor expression and function might
provide insights into the pathophysiology of insulin
resistance and its association with hypertension (Reynolds
et al 2002). Evidence for the role of neuroendocrine stress
in genesis of the metabolic syndrome comes from the work
of Brunner and colleagues (2002) who found 24-hour
cortisol metabolite and normetanephrine outputs were higher
among cases (n = 30) than controls (n = 153) drawn from
the Whitehall II cohort of middle aged working men.
Hyperlipidemia
Hyperlipidemia is said to be common in Cushing’s syndrome
with hypercholesterolemia and hypertriglyceridemia being
prominent (Nashel 1986). In 25 Italian patients with
Cushing’s, high density lipoprotein (HDL) cholesterol was
lower and low density lipoprotein (LDL) cholesterol higher
than in matched controls (Faggiano et al 2003). However,
neither total cholesterol nor HDL cholesterol were elevated
in Cushing’s syndrome compared with controls in another
study of 41 Italians with active Cushing’s syndrome (Terzolo
et al 2004). Total cholesterol and triglycerides were elevated
in 28 patients in Italy with subclinical Cushing’s syndrome
(Tauchmanova et al 2002). In 15 subjects who had had
Cushing’s disease cured over 5 years previously, total and
LDL cholesterol and lipoprotein (a) concentrations remained
higher than in 30 Italian controls (Colao et al 1999). In 10
normotensive healthy men we found 5 days’ cortisol
treatment did not alter plasma cholesterol, triglycerides,
HDL, or LDL concentrations (Table 1). These data suggest
that more prolonged periods of cortisol excess are required
to produce dyslipidemia.Vascular Health and Risk Management 2005:1(4) 295
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In a general Scottish population (n = 439), Fraser and
colleagues (1999) found cortisol excretion rate correlated
negatively with HDL cholesterol and this correlation
remained after multiple regression analysis. In a study of
226 Swedes, Walker et al (2000) found higher plasma
cortisol associated with higher triglycerides in women, but
not in men. In 28 Swedish men, a rise in morning salivary
cortisol correlated with triglycerides (Wallerius et al 2003),
and in 509 South Asians, 9 am cortisol was strongly
associated with triglyceride concentration (Ward et al 2003).
Other risk factors
Hyperhomocysteinemia and lower folate concentrations
have been reported in 41 Italian patients with Cushing’s
syndrome and homocysteine levels were significantly
associated with midnight serum cortisol and serum folate
(Terzolo et al 2004). Folate concentrations were all within
the normal range in Cushing’s syndrome, but homocysteine
was elevated. Patients in remission were comparable with
controls and the lower folates (4.9 ± 2.8 Cushing’s,
7.2 ± 2.8 µmol/L control) did not fully account for the
increase in homocysteine levels (17.8 ± 4.1 Cushings,
12.3 ± 4.2 µmol/L control) which related to serum cortisol
(Terzolo et al 2004). These same workers reported no
differences in fibrinogen concentrations, but prothrombin
time was higher and activated partial thromboplastin time
lower in Cushing’s than controls, albeit within the normal
range. We found no effect of cortisol on plasma
homocysteine concentrations in 6 normotensive healthy
men. Plasma urate was decreased, and vitamin C and vitamin
E were unchanged. There was a small fall in tissue
plasminogen activator, but not in plasminogen activator
inhibitor-1 (Table 1).
Faggiano et al (2003) found higher carotid intimamedia
thickness and lower systolic lumen diameter and
distensibility coefficient in 25 patients with Cushing’s
disease than controls. Artherosclerotic plaques were found
in over 30% of patients. Plaques and carotid intimamedia
thickness were also elevated in subclinical Cushing’s
syndrome, as was plasma fibrinogen (Tauchmanova et al
2002).
The Norwegian Tromsø study of 460 men and 486
women suggested serum calcium may be a predictor of
cardiovascular disease in men (Jorde et al 1999). In
epidemiologic studies, calcium correlates positively with
blood pressure, blood glucose, and serum cholesterol. In
our studies of 5 days’ cortisol administration, corrected
plasma calcium was unchanged (Table 1).
Mechanisms of cortisol-induced
hypertension
Hemodynamics
Both cardiac output and peripheral resistance have been
reported to be elevated in Cushing’s syndrome (Agrest et al
1974). Administration of cortisol to normotensive healthy
subjects over 5 days leads to elevation of blood pressure,
particularly systolic and mean, but also diastolic pressure
in some studies, in association with significant increase in
cardiac output, but no change in calculated total peripheral
resistance (Connell et al 1987; Pirpiris et al 1993). Renal
vascular resistance is elevated (Connell et al 1987). The rise
in cardiac output may reflect the concomitant rise in plasma
volume (Connell et al 1987), but it is not essential for
development of hypertension. Pretreatment with the
β-blocker atenolol prevented the rise in cardiac output, but
did not prevent the rise in blood pressure, which in this case
was associated with a rise in peripheral resistance (Pirpiris
et al 1993). Conversely, the calcium channel blocker
felodipine, which reduces peripheral resistance, had no effect
on the rise in blood pressure produced by cortisol, which,
in this case, was associated with increased cardiac output
(Whitworth et al 1994). Cortisol-induced hypertension is
normally associated with an increase in cardiac output, but
the latter is not essential for a blood pressure rise, which
can be mediated either by output, or by resistance.
Volume
Plasma volume is said to be increased, but total exchangeable
sodium was normal in 11 patients with Cushing’s disease
and not correlated with hypertension (Ritchie et al 1990).
Plasma volume, extracellular fluid volume (ECFV), and
exchangeable sodium are all increased by cortisol in healthy
normotensive subjects (Connell et al 1987). The increase in
extracellular fluid volume is unlikely to be essential for the
blood pressure rise as sodium restriction completely
prevented the rise in ECFV produced by ACTH without
abolishing the rise in blood pressure (Connell et al 1988).
Adrenocorticotrophic hormone hypertension is explicable
solely in terms of increased cortisol secretion (Whitworth,
Saines, et al 1984). Sodium restriction substantially reduced
the rise in exchangeable sodium, but did not modify the
rise in plasma volume. However, these factors are unlikelyVascular Health and Risk Management 2005:1(4) 296
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to be critical for cortisol-induced hypertension as the
mineralocorticoid antagonist spironolactone, which blocks
the sodium retention produced by cortisol, does not prevent
the rise in blood pressure (Williamson et al 1996). Further,
synthetic glucocorticoids, which are natriuretic, produce
elevations of blood pressure without any urinary sodium
retention or increase in body weight or plasma volume
(Whitworth et al 1989). Cortisol-induced hypertension is
not simply explained by mineralocorticoid-induced salt and
water retention.
Sympathetic nervous system
Plasma and urine catecholamine concentrations were normal
in Cushing’s disease (n = 11), but cardiac sensitivity to the
β-receptor agonist isoprenaline was increased, without
increased β-receptor density (Ritchie et al 1990). In cortisol-
treated normotensive healthy subjects measures of
sympathetic nervous activity, including plasma catechols
(Connell et al 1987), resting noradrenaline spillover rate
(Pirpiris et al 1992), reflex sympathetic function, (cold
pressor, hand grip, mental arithmetic) (Tam, Kelly, et al
1997), and neuropeptide Υ concentrations (Whitworth et al
1994a) were unchanged. Muscle sympathetic vaso-
constrictor activity measured directly from peroneal nerve
recordings was decreased by cortisol (Macefield et al 1998).
Hypertension was amplified, not abolished, by autonomic
blockade (Tam, Williamson, et al 1997). Cortisol-induced
hypertension cannot be ascribed to sympathetic nervous
system overactivity. Pressor responsiveness to catechols is
increased by cortisol treatment (Pirpiris et al 1992). This
may be, at least in part, a consequence of suppression of
sympathetic nervous activity.
Vasopressor hormones
Cortisol has a range of effects on the renin–angiotensin
system. Renin substrate (angiotensinogen) may be increased
in Cushing’s syndrome, but renin and angiotensin are usually
normal (Tenschert et al 1985; Ritchie et al 1990). Therapy
with angiotensin converting enzyme inhibitors or
angiotensin II receptor antagonists has variable effects
(Vetter et al 1976; Saruta et al 1986). Pressor responsiveness
to angiotensin II is increased (Saruta et al 1986). In cortisol
treated normal subjects, plasma renin and angiotensin II
concentrations were decreased (Connell et al 1987).
Angiotensin II pressor responsiveness was moderately
increased (Whitworth et al 1988) and this is likely to be
explained, at least in part, by decreased plasma concentration
of angiotensin II leading to upregulation of angiotensin
receptors. The well recognised glucocorticoid stimulated
increase in angiotensinogen does not lead to increased
plasma angiotensin II concentrations, and it is unlikely to
be a key causal mechanism in human glucocorticoid
hypertension.
In an Italian study of Cushing’s disease, vasopressin
(AVP) was higher in 13 hypertensives than 11 normotensives
and surgical treatment reduced AVP (Giuditta et al 2004).
We did not observe any alteration in plasma AVP
concentrations in cortisol-treated normotensive healthy men
(Connell et al 1987). Thromboxane has been reported to
correlate with cortisol concentrations in both healthy
subjects (n = 19) and those at high cardiovascular risk
(n = 31) (Fimognari et al 1996), but information in other
conditions is limited. Plasma endothelin concentrations are
elevated in Cushing’s syndrome (n = 13), but did not
correlate with blood pressure, plasma cortisol levels, or
urinary cortisol excretion (Kirilov et al 2003). In 9
normotensive healthy men treated with cortisol we observed
a nonsignificant rise in urine endothelin excretion after
5 days (Table 2). The role of insulin as a mediator of
hypertension has been the subject of much research. We
observed rises in blood pressure and plasma glucose and
insulin concentrations in normotensives treated with cortisol,
but treatment with the somatostatin analogue octreotide,
which reversed the rise in insulin, had no effect on blood
pressure, which suggests the two factors are not causally
related (Whitworth et al 1994b).
Table 2 Effects on vasoactive hormones of cortisol
administration (200 mg/day) for 5 days in normotensive healthy
men
Parameter n Control Cortisol p
APRC (pmol A1/ml/h) 16 5.0 ± 0.72 0.7 ± 0.09 < 0.001
Urine endothelin excretion
(ng/day) 9 39 ± 75 2  ± 14 ns
Urine 6 keto PGF 1α/Cr
(ng/mmol) 9 45 ± 73 6  ± 5n s
Urine 2, 3 dinor 6 keto
PGF1α/Cr (ng/mmol) 9 353 ± 41 462 ± 73 0.039
Urine cGMP (nmol/day) 9 522 ± 51 911 ± 961 0.004
NOTE: Results shown as mean ± s.e.m.
Abbreviations: APRC, active plasma renin concentration; PG, prostaglandin; Cr,
creatinine; cGMP, cyclic guanosine monophosphate; ns, nonsignificant.Vascular Health and Risk Management 2005:1(4) 297
Cardiovascular consequences of cortisol excess
Vasodilator hormones
Cushing’s syndrome is reported to be associated with
reduced activity of the kallikrein-kinin system and
prostaglandins (Saruta 1996), but in another study kinin
system components were higher (Shimamoto et al 1995).
Urinary kallikrein activity rose in healthy subjects treated
with cortisol (Whitworth, van Leeuwen, et al 1984). Atrial
natriuretic peptide is increased in Cushing’s syndrome
(Yamaji et al 1988) as it is by cortisol treatment in normal
subjects (Connell et al 1987). Accordingly there is no
evidence to suggest atrial naturiuretic peptide deficiency is
important in the aetiology of the hypertension.
We have measured urinary prostanoids in 9 cortisol-
treated normotensive subjects: 6 keto prostaglandin (PG)
FIα/creatinine ratio (ng/mmol) was not significantly
changed; and 2, 3 dinor 6 keto PG FIα/creatinine (ng/mmol)
rose (Table 2). These studies provide no evidence for
vasodilator prostanoid deficiency. Urinary cyclic guanosine
monophosphate was also increased (Table 2). In another
study, the cyclooxygenase inhibitor indomethacin did not
modify the magnitude of changes in pressor responsiveness
to phenylephrine or angiotensin II produced by cortisol
(Whitworth et al 1988).
Saruta (1996) reported low urinary excretion of reactive
nitrogen intermediates (a marker of vasodilator nitric oxide
activity) in a patient with Cushing’s syndrome, even after
L-arginine administration. In healthy men on a low nitrate
diet, we demonstrated that cortisol administration was
associated with a fall in plasma reactive nitrogen
intermediates, but not in L-arginine or asymmetric dimethyl
arginine concentrations (Kelly, Tam, et al 1998). L-arginine
did not prevent cortisol-induced rises in blood pressure
(Kelly et al 2001). Cortisol also inhibits cholinergic dilation
in the forearm, similar in magnitude to the inhibition
produced by nitric oxide synthase (Mangos, Walker, et al
2000). L-arginine transport is normal in cortisol-treated
subjects (Chin-Dusting et al 2003). Inhibition of vasodilator
nitric oxide is a strong candidate for the genesis of
glucocorticoid hypertension (Kelly, Tam, et al 1998;
Whitworth et al 2000).
Summary
There is increasing evidence that cortisol contributes to
cardiovascular risk, not only in Cushing’s syndrome, but
more generally. Hypertension, truncal obesity, hyper-
glycemia, insulin resistance, and dyslipidemia are all
important in this regard. Glucocorticoid hypertension is not
explicable in terms of mineralocorticoid-induced sodium
retention and volume expansion. Inhibition of vasodilator
nitric oxide is a strong candidate mechanism in the
development of hypertension. Therapies should be aimed
at lowering cardiovascular risk in patients with Cushing’s
syndrome, which will probably need to target multiple
metabolic and hemodynamic abnormalities.
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